KMR Group has just completed its latest upload of current site performance data into the Site Scorecard Tool.
KMR Group has just completed its latest upload of current site performance data into the Site Scorecard Tool. Site Scorecard contains the industry’s only source for vetted site performance data on interventional clinical trials, providing companies with aggregated details on a given site’s clinical trial performance directly from 12 major biopharma companies. The tool now contains over 125,000 unique records of global site performance information, at 40,000 distinct sites in all regions and all indications.
The Site Scorecard saves companies both time and money by providing access to sites with experience in interventional trials by disease as well as global performance rankings and actual performance data for each site in the search. This specificity around disease and performance is unique to the industry as many listing services provide names and addresses around sites, but the details around their experience can be murky and difficult to discern, and the performance data just doesn’t exist. Companies spend a lot of time trying to figure out which sites can deliver patients and at what rate, the Site Scorecard tool takes a lot of assumptions out of that equation. And by providing performance data on interventional studies, the data is more useful in that it provides a more meaningful estimate of a given sites ability to recruit patients for purposes of clinical trials. So although the tool may not list the “most” sites, it has neatly and effectively lifted the burden from those trying to navigate numerous site lists to sites which have experience and can deliver patients.
The tool aims to provide clarity around expectations for a given sites recruitment potential by using a fact-based, performance based approach. Companies can identify the top performing sites based on a variety of factors, including volume of subjects randomized, the speed of actual recruitment or drop-out rate to name just a few. The data can be used for purposes of planning and forecasting, and it can also be used to dialogue with the site to ensure expectations are on target.
KMR Group has spent the last five years developing and refining Site Scorecard, along with an internal site coding application, which gives us the ability to take site information from across disparate companies and create one unique record per site along with a standardized name and address. This unique record is what allows for aggregation of performance data across companies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.